Eris Lifesciences (BOM:540596) Change In Receivables : ₹0 Mil (TTM As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Eris Lifesciences Change In Receivables?

Eris Lifesciences's change in receivables for the quarter that ended in Mar. 2024 was ₹0 Mil. It means Eris Lifesciences's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

Eris Lifesciences's change in receivables for the fiscal year that ended in Mar. 2024 was ₹-571 Mil. It means Eris Lifesciences's Accounts Receivable increased by ₹571 Mil from Mar. 2023 to Mar. 2024 .

Eris Lifesciences's Accounts Receivable for the quarter that ended in Mar. 2024 was ₹4,220 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Eris Lifesciences's Days Sales Outstanding for the three months ended in Mar. 2024 was 70.37.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Eris Lifesciences's liquidation value for the three months ended in Mar. 2024 was ₹-20,129 Mil.

Eris Lifesciences Change In Receivables Historical Data

The historical data trend for Eris Lifesciences's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eris Lifesciences Change In Receivables Chart

Eris Lifesciences Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Change In Receivables

Get a 7-Day Free Trial

-747.86

158.96

-204.80

-1,171.38

-570.93

Eris Lifesciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Eris Lifesciences Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

Eris Lifesciences (BOM:540596) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Eris Lifesciences's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	4220.24	/	5472.65	*	91
=	70.37

2. In Ben Graham's calculation of liquidation value, Eris Lifesciences's accounts receivable are only considered to be worth 75% of book value:

Eris Lifesciences's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	14028.53	-	38268.06	+	0.75 * 4220.24	+	0.5 * 1890.32
=	-20,129

Eris Lifesciences Change In Receivables Related Terms

Thank you for viewing the detailed overview of Eris Lifesciences's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Eris Lifesciences (BOM:540596) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eris Lifesciences Ltd (BOM:540596) » Definitions » Change In Receivables

Traded in Other Exchanges

ERIS:India

Address

Ramdas Road, Plot No. 142/2, Shivarth Ambit, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad, GJ, IND, 380054

Website

https://www.eris.co.in

Eris Lifesciences Ltd is an India-based company engaged in the manufacturing and sale of branded pharmaceutical formulations. It focuses on Lifestyle therapies such as Diabetes Care, Cardiac Care, Nutrition, Central Nervous System, and others. The company operates in a single segment that is pharmaceuticals. Some of its brands include Glimisave, Cyblex, Eritel, Atorsave and Crevast.

Eris Lifesciences (BOM:540596) Headlines

No Headlines